The Ser311Cys variation in the paraoxonase 2 gene increases the risk of type 2 diabetes in northern Chinese

Journal of Genetics

Volumn 87, Issue 2, 2008, Pages 165-169

  Qu, Yanchun ^a,b,c   Yang, Ze ^c   Jin, Feng ^f   Sun, Liang ^c   Zhang, Chuanfang ^a   Ji, Linong ^e   Sun, Hong ^d   Wang, Binyou ^d   Wang, Li ^a  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e PEKING UNIVERSITY   (China)

^f INSTITUTE OF PSYCHOLOGY   (China)

Author keywords

Case control; Northern Chinese; Paraoxonase 2 gene; Type 2 diabetes mellitus (T2DM)

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CYSTEINE; SERINE;

AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; BLOOD PRESSURE; CASE CONTROL STUDY; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REGRESSION ANALYSIS;

AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CASE-CONTROL STUDIES; CHINA; CYSTEINE; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SERINE;

EID: 50249182988     PISSN: 00221333     EISSN: 00221333     Source Type: Journal    
DOI: 10.1007/s12041-008-0025-3     Document Type: Article

References (19)

1. Aynacioglu A. S. and Kepekci Y. 2000 The human paraoxonase Gln-Argl92 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int. J. Cardiol. 74, 33-37.
2. Chiu K. C., Chuang L. M., Chu A., Lu J., Hu J. and Fernando S. 2004 Association of paraoxonase 1 polymorphism with beta-cell function: a case of molecular heterosis. Pancreas 28, 96-103.
3. Ferguson J. J. and Randall O. S. 1986 Systolic, diastolic, and combined hypertension. Differences between groups. Arch. Intern. Med. 146, 1090-1093.
4. Ferretti G., Bacchetti T., Busni D., Rabini R. A. and Curatola G. 2004 Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab. 89, 2957-2562.
5. Fortunato G., Rubba P., Panico S., Trono D., Tinto N., Mazzaccara C. et al. 2003 A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis 167, 141-148.
6. Hegele R. A., Connelly P. W., Scherer S. W., Hanley A. J., Harris S. B., Tsui L. C. et al. 1997 Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82, 3373-3377.
7. Ikeda Y., Suehiro T., Ohsaki F., Arii K., Kumon Y. and Hashimoto K. 2003 Relationships between polymorphisms of the human serum paraoxonase gene and insulin sensitivity in Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 60, 79-85.
8. Jarvik G. P., Jampsa R., Richter R. J., Carlson C. S., Rieder M. J., Nickerson D. A. et al. 2003 Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 13, 291-295.
9. Mackness B., Durrington P. N., Abuashia B., Boulton A. J. and Mackness M. I. 2000 Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci. London 98, 355-363.
10. Mackness B., McElduff P. and Mackness M. I. 2005 The paraoxonase-2-310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus. J. Intern. Med. 258, 363-368.
11. Mochizuki H., Scherer S. W., Xi T., Nickle D. C., Majer M., Huizenga J. J. et al. 1998 Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213, 149-157.
12. Nakamura Y., Kakoki M. and Yamakado M. 1996 The effect of age on glucose tolerance and plasma insulin level in hypertensive and normotensive subjects. Hypertens. Res. 19, 23-26.
13. Oliveira S. A., Mansur A. P., Ribeiro C. C., Ramires J. A. and Annichino-Bizzacchi J.M. 2004 PON1M/L55 mutation protects high-risk patients against coronary artery disease. Int. J. Cardiol. 94, 73-77.
14. Primo-Parmo S. L., Sorenson R. C., Teiber J. and La Du B. N. 1996 The human serum paraoxonase/arylesterase gene (PON1) is one member of multigene family. Genomics 33, 498-507.
15. Prochazka M., Thompson D. B. and Scherer S. W. 1995 Linkage and association of insulin risistance and NIDDM with markers at 7q21.3-q22.1 in the Pima Indians. Diabetes 44 (suppl.), 42.
16. Robertson K. S., Hawe E., Miller G. J., Talmud P. J. and Humphries S. E. 2003 Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim. Biophys. Acta. 1639, 203-212.
17. Sanghera D. K., Aston C. E., Saha N. and Kamboh M. I. 1998 DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum. Genet. 62, 36-44.
18. Senti M., Tomas M., Fito M., Weinbrenner T., Covas M. I., Sala J. et al. 2003 Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88, 5422-5426.
19. Wheeler J. G., Keavney B. D., Watkins H., Collins R. and Danesh J. 2004 Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363, 689-695.